NERM
REGN icon

New England Research & Management’s Regeneron Pharmaceuticals REGN Stock Holding History

New England Research & Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.17M Buy
3,475
+2,900
+504% +$1.97M 0.84% 34
2026
Q1 		$444K Buy
575
+75
+15% +$57.4K 0.19% 117
2025
Q4 		$386K Buy
+500
New +$340K 0.17% 115
2025
Q3 		– Sell
-605
Closed -$318K – 172
2025
Q2 		$318K Hold
605
– – 0.15% 128
2025
Q1 		$384K Buy
+605
New +$416K 0.2% 114
2023
Q3 		– Sell
-940
Closed -$675K – 166
2023
Q2 		$675K Buy
+940
New +$725K 0.39% 78
2022
Q4 		– Sell
-932
Closed -$642K – 173
2022
Q3 		$642K Sell
932
-59
-6% -$37.1K 0.4% 82
2022
Q2 		$586K Buy
991
+45
+5% +$29.3K 0.34% 102
2022
Q1 		$661K Sell
946
-29
-3% -$18.3K 0.34% 89
2021
Q4 		$616K Buy
975
+360
+59% +$221K 0.3% 101
2021
Q3 		$372K Sell
615
-1,045
-63% -$649K 0.19% 127
2021
Q2 		$927K Sell
1,660
-200
-11% -$101K 0.48% 74
2021
Q1 		$880K Buy
1,860
+725
+64% +$353K 0.48% 72
2020
Q4 		$548K Sell
1,135
-470
-29% -$254K 0.34% 95
2020
Q3 		$898K Buy
+1,605
New +$973K 0.65% 52
2017
Q1 		– Sell
-730
Closed -$268K – 184
2016
Q4 		$268K Sell
730
-125
-15% -$47.5K 0.21% 139
2016
Q3 		$344K Sell
855
-290
-25% -$116K 0.29% 112
2016
Q2 		$400K Buy
1,145
+170
+17% +$65.5K 0.34% 103
2016
Q1 		$351K Buy
+975
New +$402K 0.3% 110
2014
Q1 		– Sell
-2,498
Closed -$688K – 154
2013
Q4 		$688K Buy
+2,498
New +$718K 0.66% 51

Other funds holding REGN

Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
MCI
McDonald Capital Investors Orinda, California $1.37B AUM 1.88% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Retirement Systems of Alabama
Retirement Systems of Alabama Montgomery, Alabama $33.2B AUM 38.15% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Parnassus Investments
Parnassus Investments San Francisco, California $37.4B AUM 35.42% 1-Year Est. Return

New England Research & Management's REGN Position: Q2 2026 in Review

New England Research & Management increased its Regeneron Pharmaceuticals (REGN) stake by 504% in Q2 2026, buying an estimated $1.97M and bringing the position to 3,475 shares worth $2.17M. The position accounts for 0.84% of the portfolio, ranked #34.

New England Research & Management first reported a position in REGN in Q4 2013 and has held it in 20 quarters since. 518 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • New England Research & Management held 3,475 shares of Regeneron Pharmaceuticals worth $2.17M as of Q2 2026.
  • New England Research & Management bought 2,900 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $1.97M.
  • Regeneron Pharmaceuticals made up 0.84% of New England Research & Management's portfolio in Q2 2026, its #34 holding.
  • New England Research & Management first reported a position in Regeneron Pharmaceuticals in Q4 2013 and has held it in 20 quarters since.
  • 518 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on New England Research & Management's 13F filing for Q2 2026, filed 9 Jul 2026.